Phase 2 N=30 Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Median Progression-Free Survival — 10.4 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
Phase 2 N=41 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Breast Cancer
Primary: Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy — 39 percentage of tumors
Phase 2 N=223 A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
Rheumatoid Arthritis
Primary: Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64) — 45.1; 68.4; 31.6; 61.8 percentage of participants
Phase 2 N=152 Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change in ADAS-Cog for MCI Subjects — 5.664; -0.710 Scores on a scale
Phase 2 N=63 A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
Healthy
Primary: Adverse Events — 46; 28; 29; 36 number of reported events
Phase 2 N=26 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Melanoma (Skin)
Primary: Clinical Tumor Regression — 1; 1; 9; 2 Participants
Phase 2 N=10 Flumazenil for the Treatment of Primary Hypersomnia
Hypersomnia · Primary Hypersomnia · Idiopathic Hypersomnia
Primary: Change in Psychomotor Vigilance Task (PVT) Median Reaction Time — -9.86; -4.46 msec — p=0.77
Phase 2 N=9 Safety and Tolerability of Dabigatran Etexilate in Adolescents
Venous Thromboembolism
Primary: Number of Patients With Bleeding Events (Major and Minor) — 0 Participants
Phase 2 N=30 Study of Capecitabine to Treat Recurrent High Grade Gliomas
Malignant Glioma
Primary: Percentage of Participants With Progression-free Survival. — 21.7 percentage of participants with PFS6
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Phase 2 N=69 Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Overall Survival Rate — 66.0; 25.02; 11.3 percentage of participants
Phase 2 N=20 Cranial Electrotherapy Stimulation in Burned Patients
Post Traumatic Stress Disorders · Burns
Primary: Mean Post-Traumatic Stress Questionnaire-Military (PCL-M) Score — 53.8; 56.7; 48.8; 50.4 Score
Phase 2 N=356 Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Type 2 Diabetes
Primary: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12. — -5.3; -14.6; -25.1; -27.2 mg/dL — p=0.1819
Phase 2 N=18 Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
Chemotherapeutic Agent Toxicity · Neurotoxicity · Pain
Primary: Change in Pain Score — 2.4 units on a scale